Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radiation Therapy Clear all
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

NCT00846742
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Stanford V Chemotherapy, Radiation Therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
6
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Not applicable Interventional

Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device

NCT05096286
View directory record Official record
Conditions
Intracranial Metastatic Disease From Any Solid Malignancy
Interventions
Ethos Therapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 22, 2026, 9:35 PM EDT
Active, not recruiting No phase listed Observational

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

NCT04384770
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
CT-guided Stereotactic Body Radiation Therapy, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Not applicable Interventional

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

NCT04699773
View directory record Official record
Conditions
Glioma, Glioblastoma, Brain Tumor
Interventions
LITT, Hypofractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Completed No phase listed Observational

Determining Molecular Drivers of Radiation Dermatitis

NCT04764682
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Radiation Therapy for Glioblastoma Multiforme

NCT01466686
View directory record Official record
Conditions
High Grade Glioma
Interventions
Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Phase 2 Interventional

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

NCT05052957
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions
P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy, temozolomide, Filgrastim, carmustine
Biological · Drug · Radiation
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Screening for Age-Related Skeletal Muscle Dysfunction

NCT02277236
View directory record Official record
Conditions
Sarcopenia
Interventions
DXA scanning, CT imaging
Radiation
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
45 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 22, 2026, 9:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Outcomes Follow-up of Glenoid Anchor Peg Component Fixation

NCT02983357
View directory record Official record
Conditions
Arthritis
Interventions
CT, X-Ray, Physical assessment, Questionnaire
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
44 Years to 94 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Phase 2 Interventional

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

NCT04774419
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Intensity modulated radiation therapy (IMRT), Dostarlimab, Hypofractionated IMRT
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Not yet recruiting Not applicable Interventional

Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation

NCT07648407
View directory record Official record
Conditions
Nonmelanoma Skin Cancer, Actinic Keratosis
Interventions
Microneedling, Trichloroacetic acid peel
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Indianapolis, Indiana • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)

NCT02057939
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzalutamide, Androgen Deprivation, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
New Brunswick, New Jersey • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 22, 2026, 9:35 PM EDT
Terminated Phase 2 Interventional Results available

FLT PET Imaging for Cervical Cancer

NCT01075412
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
[F18]Fluorothymidine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Light and Exercise on Human Circadian Rhythms and Performance

NCT02747719
View directory record Official record
Conditions
Circadian Rhythm
Interventions
Light and exercise
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Terminated Phase 1 Interventional

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

NCT02659800
View directory record Official record
Conditions
Lymphopenia, Malignant Glioma
Interventions
Laboratory Biomarker Analysis, NT-I7, Placebo
Other · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Not applicable Interventional

Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy

NCT01794481
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Resistance Exercise Training (RET)
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 22, 2026, 9:35 PM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 9:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dosimeter Location in Pain Physicians

NCT06309407
View directory record Official record
Conditions
RAD
Interventions
Hand Dosimeters, Standard Practice
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Phase 2 Interventional

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000
View directory record Official record
Conditions
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Interventions
aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
Biological · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Terminated Not applicable Interventional

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Cyclophosphamide, Total Body Irradiation, Cyclosporine A, Mycophenylate mofetil, Umbilical cord blood
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 9:35 PM EDT
Recruiting Not applicable Interventional

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

NCT07643012
View directory record Official record
Conditions
Endometrial Cancer
Interventions
MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 22, 2026, 9:35 PM EDT